Roche Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Roche Bundle
Download Your Competitive Advantage
Uncover the strategic positioning of a company's product portfolio with the BCG Matrix, a powerful tool that categorizes products into Stars, Cash Cows, Dogs, and Question Marks based on market growth and share. This insightful framework helps businesses make informed decisions about resource allocation and future investments. Don't miss out on the detailed analysis and actionable strategies; purchase the full BCG Matrix report today to unlock your company's growth potential.
Stars
Vabysmo (faricimab)
Vabysmo, a groundbreaking treatment for serious eye conditions like wet age-related macular degeneration and diabetic macular edema, has been a significant growth engine for Roche. In 2024, Vabysmo sales reached CHF 2.2 billion, a substantial increase from its launch period, and this momentum continued into Q1 2025 with strong market penetration. Its success is directly attributable to its efficacy in a growing therapeutic area, positioning it firmly as a Star in Roche's portfolio.
Phesgo (pertuzumab/trastuzumab/hyaluronidase)
Phesgo, a key breast cancer therapy from Roche, is a prime example of a Star in the BCG Matrix. Its sales surged by an impressive 55% in the first half of 2025, a testament to its growing market share and effectiveness. This remarkable growth is fueled by increasing patient adoption and its unique at-home administration convenience, solidifying its position as a leader in its therapeutic area.
Ocrevus (ocrelizumab)
Ocrevus (ocrelizumab) continues to be a powerhouse for Roche in the multiple sclerosis market, consistently generating substantial revenue. In 2023, Ocrevus achieved sales of CHF 3.7 billion, demonstrating its enduring market strength.
The drug's established efficacy, coupled with the recent launch of a subcutaneous formulation, has bolstered its competitive standing and accessibility for patients. This strategic move is expected to further solidify Ocrevus's position and sales trajectory.
Ocrevus is undeniably a star performer within Roche's pharmaceutical division, representing a critical revenue driver in the immunology segment. Its sustained high performance is crucial for the company's overall financial health and market leadership in treating multiple sclerosis.
Hemlibra (emicizumab)
Hemlibra, Roche's innovative treatment for hemophilia A, is a clear Star in the company's portfolio. Its significant sales growth and increasing market share, especially in the non-inhibitor segment, solidify its position. In 2023, Hemlibra achieved CHF 4.5 billion in sales, representing a 32% increase year-over-year, underscoring its strong performance in a growing hemophilia market.
- Strong Sales Growth: Hemlibra's 2023 sales reached CHF 4.5 billion, a 32% increase from the previous year.
- Market Leadership: It holds a dominant position in the hemophilia A market, particularly for patients with inhibitors.
- Key Growth Driver: Hemlibra is consistently identified as a primary contributor to Roche's overall revenue expansion.
- Future Potential: Continued innovation and expanded indications are expected to maintain its Star status.
Xolair (omalizumab)
Xolair (omalizumab), a significant product for Roche, is positioned as a Star in the BCG Matrix due to its strong market performance and expanding applications. Its established success in treating allergic asthma and chronic spontaneous urticaria, coupled with its recent advancements into food allergies, highlights robust growth potential. This product is a key driver of Roche's pharmaceutical revenue, reflecting its high market share in a growing market.
Xolair's continued expansion into new indications, such as severe eosinophilic asthma and allergic rhinitis, further solidifies its Star status. The drug's ability to address unmet medical needs in allergy management contributes to its sustained demand. In 2023, Xolair, co-developed with Novartis, generated approximately $2.7 billion in sales for Roche, underscoring its importance as a revenue generator.
- Xolair's Market Position: Star
- Key Growth Drivers: Expansion into food allergies, sustained uptake in existing indications.
- Revenue Contribution: Significant contributor to Roche's pharmaceutical sales, generating approximately $2.7 billion in 2023.
- Future Outlook: High-growth trajectory expected due to broadened indications and strong market presence.
Roche's Stars: Shining Bright in the Pharma Universe
Stars in Roche's portfolio represent products with high market share in high-growth markets, demanding significant investment but also generating substantial returns. Vabysmo, Phesgo, Ocrevus, Hemlibra, and Xolair exemplify this category, showcasing impressive sales figures and strategic market positioning.
These products are critical for Roche's continued success, driving revenue and solidifying its leadership in key therapeutic areas. Their performance in 2023 and early 2025 data indicates a strong trajectory, suggesting they will remain vital contributors to the company's financial health.
The consistent growth and market penetration of these Stars underscore Roche's strategic focus on innovation and addressing significant unmet medical needs.
| Product | 2023 Sales (CHF) | YoY Growth (2023) | Key Indications | Market Position |
|---|---|---|---|---|
| Vabysmo | 2.2 billion (2024) | N/A (Launched later) | Wet AMD, DME | Star |
| Phesgo | N/A (Strong H1 2025 growth) | 55% (H1 2025) | Breast Cancer | Star |
| Ocrevus | 3.7 billion | N/A (Consistent performer) | Multiple Sclerosis | Star |
| Hemlibra | 4.5 billion | 32% | Hemophilia A | Star |
| Xolair | ~2.7 billion (Roche's share) | N/A (Strong growth) | Allergic Asthma, CSU, Food Allergies | Star |
What is included in the product
Detailed Word Document
The Roche BCG Matrix categorizes products by market share and growth, guiding strategic investment decisions.
Customizable Excel Spreadsheet
Strategic clarity by visualizing each business unit's market share and growth potential.
Cash Cows
Roche Diagnostics (Core Business)
Roche Diagnostics' core business stands as a titan in in-vitro and tissue-based cancer diagnostics, boasting a vast portfolio of proven tests and systems. This segment is a consistent powerhouse, reliably generating significant and stable cash flow. This is largely attributable to its dominant market share within a well-established, mature market.
While facing some localized pricing challenges, this diagnostics division remains a cornerstone of Roche's profitability and overall operations. In 2024, Roche's Diagnostics division reported impressive results, with sales reaching CHF 17.1 billion, underscoring its role as a formidable cash cow.
Tecentriq (atezolizumab)
Tecentriq (atezolizumab) continues to be a vital revenue generator for Roche, solidifying its position as a mature product. While its rapid growth phase has passed, its established market share in multiple cancer types ensures a steady income stream. This reliable cash flow, with minimal need for substantial new investment, clearly marks Tecentriq as a Cash Cow within Roche's portfolio.
Kadcyla (trastuzumab emtansine)
Kadcyla, an antibody-drug conjugate, is a significant contributor to Roche's portfolio, particularly in the breast cancer market. Its established presence and consistent sales performance position it as a reliable revenue generator.
In 2024, Kadcyla continued to demonstrate robust sales, reflecting its mature yet strong market position. This steady income stream requires less aggressive marketing compared to emerging therapies, solidifying its role as a cash cow for Roche.
Alecensa (alectinib)
Alecensa, a key product in Roche's oncology portfolio, is a prime example of a cash cow within the BCG matrix. This targeted therapy for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) has demonstrated consistent sales growth and a robust market presence.
In 2023, Alecensa's sales reached CHF 2.4 billion, reflecting its established position and continued demand. This drug operates in a mature market where its efficacy and safety profile have secured a significant market share, minimizing the need for substantial reinvestment to maintain its status.
- Alecensa's 2023 sales: CHF 2.4 billion.
- Therapeutic area: ALK-positive NSCLC.
- Market position: Mature with high market share.
- Role in portfolio: Consistent revenue generator for Roche.
Perjeta (pertuzumab)
Perjeta (pertuzumab) is a strong performer for Roche, generating consistent and substantial revenue. Its established presence in key oncology markets, particularly outside of regions where Phesgo has gained traction, solidifies its position. In 2023, Roche reported CHF 4.3 billion in sales for Perjeta, highlighting its reliable contribution to the company's portfolio.
While the introduction of Phesgo, a combination therapy, is leading some patients to switch, Perjeta continues to hold a significant market share in its established treatment areas. This ongoing demand, even with newer alternatives, underscores its status as a Cash Cow within Roche's product lineup. The drug's efficacy in treating HER2-positive breast cancer remains a key driver of its sustained sales performance.
- Perjeta generated CHF 4.3 billion in sales in 2023 for Roche.
- It maintains a strong market share in established oncology segments.
- International market adoption contributes significantly to its reliable revenue stream.
- The drug is a key contributor to Roche's oncology business.
Diagnostics Division: A CHF 17.1 Billion Cash Cow
Roche's Diagnostics division, a cornerstone of its business, consistently generates substantial and stable cash flow. This segment, a leader in in-vitro and tissue-based cancer diagnostics, benefits from a dominant market share in a mature market. In 2024, this division achieved sales of CHF 17.1 billion, reinforcing its powerful cash cow status.
| Product | 2023 Sales (CHF billions) | Therapeutic Area | Market Position | BCG Status |
|---|---|---|---|---|
| Tecentriq | N/A (Mature) | Multiple Cancers | Established, Stable | Cash Cow |
| Kadcyla | N/A (Mature) | Breast Cancer | Strong, Consistent | Cash Cow |
| Alecensa | 2.4 | ALK-positive NSCLC | Mature, High Share | Cash Cow |
| Perjeta | 4.3 | HER2-positive Breast Cancer | Established, Significant | Cash Cow |
Full Transparency, Always
Roche BCG Matrix
The preview you see is the exact BCG Matrix report you will receive upon purchase, ensuring no discrepancies and immediate usability for your strategic planning. This comprehensive document has been meticulously designed to provide clear insights into your business portfolio, allowing you to make informed decisions without any hidden surprises or watermarks. Once bought, this fully formatted, analysis-ready file will be instantly accessible for editing, printing, or presenting to stakeholders.
Dogs
Avastin (bevacizumab)
Avastin, once a titan in oncology, now faces a challenging reality within Roche's portfolio. Its sales have seen a significant downturn, a direct consequence of losing patent protection and the subsequent surge of biosimilar alternatives. This has led to a rapid erosion of its market share in an already mature segment of the oncology market.
In 2023, Avastin's sales continued their downward trend, contributing to Roche's overall performance. While specific figures for Avastin's contribution in the most recent reporting periods are part of broader oncology segment data, the trend indicates a product that has moved past its growth phase. The strategic implication for Avastin, viewed through the lens of the BCG Matrix, places it firmly in the 'Dog' category.
Herceptin (trastuzumab)
Herceptin, a cornerstone in treating HER2-positive breast and gastric cancers, has experienced a significant downturn in revenue. This decline is directly attributable to the aggressive market penetration of biosimilar versions.
As of the latest available data, the market for Herceptin is highly saturated and mature. Roche's original Herceptin now commands a diminished market share, reflecting the intense competition.
Consequently, Herceptin is firmly positioned as a cash cow, or a product in the harvesting phase of the BCG matrix. Its contribution to Roche's overall sales is on a downward trajectory, necessitating strategic management of its remaining lifecycle.
MabThera/Rituxan (rituximab)
MabThera/Rituxan, a key product for Roche in treating blood cancers and rheumatoid arthritis, has experienced a notable decline in its market position. This erosion is largely due to the introduction of biosimilar versions, which have significantly cut into the brand's market share.
As of the latest available data, the market for MabThera/Rituxan is characterized by low growth. Roche's own sales from the drug have been considerably impacted, reflecting the competitive landscape and the shift towards newer therapeutic options within the company's portfolio.
Lucentis (ranibizumab)
Lucentis, a treatment for various eye diseases, is positioned as a Dog within Roche's BCG Matrix. Its sales have been declining, a trend exacerbated by the loss of patent protection and the emergence of strong competition. This includes newer therapies, notably Roche's own Vabysmo, which is gaining traction in the ophthalmology sector.
The market for Lucentis is characterized by intense competition, leading to a steady erosion of its market share. In 2023, the ophthalmology market saw significant advancements, with treatments for wet age-related macular degeneration (AMD) and diabetic macular edema (DME) continuing to be key areas of focus.
Given its declining market position and the availability of more advanced alternatives, Lucentis requires minimal strategic investment from Roche. The focus is shifting towards products with greater growth potential, making Lucentis a candidate for divestment or a strategy of harvesting remaining value with limited future resource allocation.
- Product: Lucentis (ranibizumab)
- Market Position: Declining market share in a competitive ophthalmology market.
- Strategic Implication: Requires minimal strategic investment due to diminishing sales and competition.
- Financial Outlook: Facing reduced revenue streams post-exclusivity and competition from newer drugs like Vabysmo.
COVID-19 Related Products
Roche's COVID-19 related products, including diagnostic tests and treatments like Ronapreve, have experienced a significant downturn in sales. This decline is directly linked to the subsiding of the pandemic and a return to more normalized demand patterns.
This category now falls into the question mark or dog quadrant of the BCG matrix for Roche, signifying a low-growth market with a diminishing market share. The company's strategic focus has shifted away from these offerings.
As of the latest available data leading up to mid-2025, the revenue contribution from these COVID-19 specific products is minimal. Roche has largely divested or de-emphasized this segment, anticipating little to no future impact on its overall financial performance.
- Sales Decline: Significant drop in revenue for COVID-19 diagnostics and treatments.
- Market Position: Now considered a low-growth, low-share segment for Roche.
- Strategic Shift: Company has pivoted focus away from these products.
- Future Impact: Minimal expected effect on Roche's overall financial results.
Roche's Portfolio: Dogs in Decline
Products like Avastin and Herceptin, once top performers, are now in the Dog category for Roche due to patent expirations and biosimilar competition. Their sales have significantly decreased, reflecting a mature market with declining market share.
MabThera/Rituxan also faces this challenge, with its market characterized by low growth and reduced sales for Roche. Lucentis, impacted by competition and newer alternatives like Vabysmo, is similarly categorized as a Dog, requiring minimal investment.
Roche's COVID-19 related products have also transitioned into this quadrant, with sales significantly down as the pandemic subsides. The company's strategic focus has shifted away from these offerings, anticipating minimal future impact.
| Product | Category | Market Trend | Strategic Implication |
|---|---|---|---|
| Avastin | Dog | Declining sales due to biosimil competition | Minimal investment, focus on harvesting remaining value |
| Herceptin | Dog | Significant revenue downturn from biosimil versions | Mature market, diminished market share |
| MabThera/Rituxan | Dog | Erosion of market position due to biosimil entry | Low growth market, reduced sales impact |
| Lucentis | Dog | Declining sales, strong competition from Vabysmo | Minimal strategic investment, potential divestment |
| COVID-19 Products | Dog | Significant sales downturn, subsiding pandemic | Low growth, diminishing market share, de-emphasized |
Question Marks
Trontinemab (Alzheimer's Disease)
Trontinemab, an investigational therapy for Alzheimer's disease, is poised to enter Phase III trials. As a potential breakthrough in a market with immense unmet needs, it currently holds zero market share, positioning it as a classic 'Question Mark' in the BCG Matrix.
The Alzheimer's treatment market is projected to reach over $100 billion by 2028, highlighting Trontinemab's substantial growth potential. However, its current lack of market presence necessitates significant ongoing investment in research, development, and future commercialization to capture a meaningful portion of this expanding sector.
Zosurabalpin (Drug-Resistant Infections)
Zosurabalpin represents a significant potential investment for Roche in the "Question Mark" category of the BCG matrix. Its development targets a critical unmet need in combating drug-resistant infections, a market segment projected to see substantial growth. The global antibiotic market was valued at approximately $45.5 billion in 2023 and is expected to grow, driven by the increasing prevalence of antimicrobial resistance (AMR).
NXT007 (Next-Generation Hemophilia A)
NXT007, Roche's promising investigational bispecific antibody for hemophilia A, is positioned as a potential future star. Its ability to target a high-growth therapeutic area with the aim of normalizing hemostasis makes it a strong candidate for significant market penetration once approved.
Currently, NXT007 is in the development phase, meaning it has zero market share. The substantial investment required for Phase III clinical trials, which are anticipated to commence in 2026, and subsequent regulatory approvals places it firmly in the question mark category of the BCG matrix. This necessitates careful resource allocation to nurture its growth potential.
Itovebi (inavolisib)
Itovebi (inavolisib), a new breast cancer treatment launched by Roche in 2024, is positioned as a Star in the BCG Matrix. While its current market share is low due to its recent introduction, it operates within the high-growth oncology sector. Projections suggest substantial sales by 2030, indicating strong future potential.
- Itovebi's Market Position: Star (low market share, high market growth)
- Launch Year: 2024
- Projected Sales Growth: Significant by 2030
- Strategic Imperative: Continued investment in marketing and distribution to capture market leadership.
Obesity Pipeline (e.g., CT-388)
Roche is making a significant push into the burgeoning obesity market with promising drug candidates like CT-388, developed in partnership with Zealand Pharma. This strategic move positions Roche as a new entrant in a sector experiencing rapid growth, where its current market share is negligible. The company anticipates substantial investment will be necessary to bring these assets to fruition and carve out a competitive position.
The obesity market is projected to be a multi-billion dollar opportunity, with estimates suggesting it could reach over $100 billion by 2030, driven by increasing prevalence of obesity and demand for effective treatments. CT-388, a GLP-1 receptor agonist, has shown promising results in early-stage trials, demonstrating significant weight loss and potential for metabolic improvement. For instance, in a Phase 2 trial, CT-388 achieved an average weight reduction of 18.8% after 24 weeks. This places it in a prime position within the BCG matrix, likely categorized as a ‘Question Mark’ due to its high growth potential but unproven market success and substantial investment requirements.
- High Growth Potential: The obesity market is expanding rapidly, with significant unmet needs and a growing patient population.
- New Entrant Status: Roche is entering this market with novel drug candidates, aiming to capture a share of a lucrative and expanding sector.
- Significant Investment Required: Developing and commercializing obesity drugs involves substantial R&D expenditure and marketing efforts.
- Competitive Landscape: While a new player, Roche will face competition from established companies and other pipeline assets entering the market.
Investing in Tomorrow: The Question Mark Strategy
Question Marks in Roche's portfolio represent products with low market share but operating in high-growth markets. These require significant investment to develop their potential, with the aim of eventually becoming Stars. Examples include investigational therapies where substantial R&D and market entry costs are still being incurred.
Trontinemab, an Alzheimer's treatment, is a prime example of a Question Mark. Despite zero current market share, the Alzheimer's market's projected growth to over $100 billion by 2028 highlights its potential. Similarly, Zosurabalpin, targeting drug-resistant infections, is in a growing market (global antibiotic market valued at $45.5 billion in 2023) but needs substantial investment to gain traction.
NXT007 for hemophilia A and CT-388 for obesity are also Question Marks. NXT007, with zero market share currently, requires significant investment for Phase III trials anticipated in 2026. CT-388 operates in the rapidly expanding obesity market, projected to exceed $100 billion by 2030, but needs substantial R&D and commercialization investment.
These products, while currently demanding significant capital, represent future growth opportunities for Roche. Their success hinges on effective development, regulatory approval, and market penetration strategies within their respective high-growth therapeutic areas.
BCG Matrix Data Sources
Our BCG Matrix leverages robust data from financial reports, market research, and industry trend analysis to provide a comprehensive view of product portfolio performance.
